STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANAB
  4. [Form 4] ANAPTYSBIO, INC Insider Trading Activity

AnaptysBio (ANAB) CEO reports RSU vesting and tax share sale via Form 4

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

AnaptysBio President and CEO Daniel Faga, who is also a director, reported the vesting of 26,838 restricted stock units (RSUs) on January 7, 2026. Each RSU converts into one share of common stock for no cash cost, increasing his directly held common shares to 493,625 and leaving 80,512 RSUs outstanding.

On January 8, 2026, Faga reported selling 14,281 shares of common stock at $44.71 per share. According to the disclosure, this sale was made solely to cover tax withholding obligations arising from the RSU vesting through a “sell to cover” transaction, and was not a discretionary trade.

Positive

  • None.

Negative

  • None.
Insider Faga Daniel
Role President, CEO
Sold 14,281 shs ($639K)
Type Security Shares Price Value
Sale Common Stock 14,281 $44.71 $639K
Exercise Restricted Stock Unit 26,838 $0.00 --
Exercise Common Stock 26,838 $0.00 --
Holdings After Transaction: Common Stock — 479,344 shares (Direct); Restricted Stock Unit — 80,512 shares (Direct)
Footnotes (1)
  1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Faga Daniel
(Last) (First) (Middle)
C/O ANAPTYSBIO, INC.
10770 WATERIDGE CIRCLE, SUITE 210
(Street)
SAN DIEGO CA 92121
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President, CEO
3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/07/2026 M 26,838 A (1) 493,625 D
Common Stock 01/08/2026 S(2) 14,281 D $44.71 479,344 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (1) 01/07/2026 M 26,838 (3) (3) Common Stock 26,838 $0 80,512 D
Explanation of Responses:
1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
3. The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
/s/ Eric Loumeau, Attorney-in-Fact 01/09/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did ANAB President and CEO Daniel Faga report?

Daniel Faga reported the vesting of 26,838 RSUs on January 7, 2026, which converted into shares of AnaptysBio common stock for no cash consideration, and a subsequent sale of 14,281 common shares on January 8, 2026 at $44.71 per share.

Why did the ANAB CEO sell 14,281 shares of AnaptysBio common stock?

The filing states that the 14,281-share sale was made to cover tax withholding obligations related to the vesting and settlement of RSUs. It was executed as a “sell to cover” transaction and is described as not a discretionary transaction by the reporting person.

How many AnaptysBio shares does Daniel Faga hold after these transactions?

After the reported transactions, Daniel Faga directly beneficially owns 493,625 shares of AnaptysBio common stock and 80,512 RSUs, each RSU representing a right to receive one share of common stock upon settlement.

What are the terms of the ANAB CEO’s restricted stock units reported here?

Each RSU represents a contingent right to receive 1 share of AnaptysBio common stock for no consideration upon settlement. The RSUs vest as to 25% of the total units annually, beginning on January 7, 2026, so long as Daniel Faga continues to provide service to the company on each vesting date.

On what dates did the AnaptysBio (ANAB) insider transactions occur?

The RSU-related transactions, including conversion into common stock, are dated January 7, 2026. The related tax “sell to cover” sale of 14,281 common shares at $44.71 per share occurred on January 8, 2026.

Is the AnaptysBio CEO’s RSU transaction a cashless exercise?

Yes. The disclosure notes that each RSU converts into one share of common stock for no consideration, meaning Faga did not pay cash to receive the 26,838 shares issued upon RSU settlement.